View Clinical Trial (Medical Research Study)

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) - NCT00875693-10021(Clinical Trial 282186)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New York
State:  
NY
Zip Code: 10021
Conditions: Acute Myelogenous Leukemia - Myelodysplastic Syndrome
Purpose: This open-label Phase I study is designed to determine the maximum tolerated dose (MTD) for CPX-351 followed by a reduced intensity conditioning regimen and incorporates a dose-escalation schedule that sequentially enrolls 6 dosing cohorts. After the determination of the MTD, the investigator reserves the option to enroll up to 10 additional subjects in an expanded safety cohort(s) at the MTD. Refractory and relapsed AML patients who meet standard institutional criteria to undergo sequential induction/reduced intensity conditioning allogeneic transplants will be offered a transplant from a related or unrelated donor (full match or 1 antigen mismatch). Cord blood transplants will not be used in this study.
Study summary:
Criteria: Inclusion Criteria: 1. Patients are included, if they fulfill at least one of the following criteria defining refractory or relapsed AML according to previously established criteria 1-3: (1) Primary induction failure (PIF) after ≥ 2 cycles of chemotherapy. (2) First relapse. (3) Relapse refractory to salvage chemotherapy (4) Second or subsequent relapse. 2. Patients with MDS, either RAEB I or RAEB II 3. Age between 18 and 70 years old. 4. Patients must have a Karnofsky Performance Status > 70. 5. Each patient must be willing to participate as a research subject and must sign an informed consent form. 6. If the patient has a history of a prior malignancy, they must be without any evidence of disease of that prior malignancy for at least 2 years before being eligible for transplant on this protocol. This excludes skin cancers that may have been excised within that 2 year period. 7. Patients must have adequate physical function measured by: 1. Cardiac: asymptomatic or if symptomatic then LVEF at rest must be > 50% and must improve with exercise. 2. Hepatic: < 3x ULN ALT and < 1.5 total serum bilirubin, unless liver is involved with the disease or there is congenital benign hyperbilirubinemia. 3. Renal: serum creatinine within normal range for age or if serum creatinine is outside the normal range, then CrCl > 60-ml/min. 4. Pulmonary: asymptomatic or if symptomatic, DLCO > 45% of predicted (corrected for hemoglobin) Exclusion Criteria: 1. Impaired renal function with a measured or calculated creatinine clearance of less than 60 ml/min. 2. Impaired hepatic function defined as a bilirubin greater than 1.5 x upper limit of normal or ALT or AST greater than 3 x normal. 3. Serious active or uncontrolled infection (Infections are controlled when patients are afebrile and hemodynamically stable for 72 hours) or medical condition. 4. Women who are pregnant or breast feeding. Women of childbearing age must use adequate contraception and have a negative pregnancy test. 5. Impaired pulmonary function with a DLCO less than 45% predicted. 6. Impaired cardiac function with an ejection fraction less than 50% of predicted by echocardiogram or MUGA. 7. Prior daunorubicin therapy with a cumulative dose of more than 368 mg/m2 or equivalent. The anthracycline agents commonly used in treating myeloid malignancies are doxorubicin, idarubicin and mitoxantron. For example, a patient who receives 7 + 3 (daunorubicin 180 mg/m2) for induction and MEC (mitoxantrone 48 mg/m2) for salvage. The cumulative daunorubicin equivalent is 180 + (48x2) = 278 mg/m2. 8. Other systemic anticancer therapy or ongoing toxicities from such therapy. 9. Patients with a history of and/or current evidence of myocardial impairment (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, congestive heart failure), resulting in heart failure by New York Heart Association Class III or IV staging. 10. Patients with Wilson disease or other Cu-related disorders.
Study is available at: Weill Cornell Medical College
New York, NY 10021
United States

Primary Contact:
Usama Gergis, MD
Email: usg2001@med.cornell.edu

Secondary Contact:
Usama Gergis, MD
Email: usg2001@med.cornell.edu
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.